AstraZeneca Acquires Fusion Pharmaceuticals for $2B to Bolster Radioconjugate Pipeline
What You Should Know:
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).The acquisition marks a major step forward in AstraZeneca delivering on its ambition to…
Continue Reading